Cisplatin

Efficacy and safety of intravenous topotecan combinatory chemotherapy tested

Published in Hematology Week, September 19th, 2005

Scientists examined the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide.

In a recent article published in the journal Lung Cancer, scientists in France reported, "This phase II study investigated the efficacy and safety of topotecan in combination with either cisplatin or etoposide in untreated extensive disease SCLC (ED SCLC). Patients with untreated ED SCLC were randomized to treatment with T/C (topotecan 1.25 mg/(m² day) IV days 1-5, cisplatin 50 mg/m² IV day 5; 41 patients) or T/E (topotecan .75 mg/(m² day) IV days 1-5, etoposide 60 mg/(m²day) IV days 1-5; 41 patients)...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hematology Week

Source: Hematology Week (2005-09-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry